Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of Company as specified in its charter)
|
Delaware
|
|
001-15697
|
|
22-3542636
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey 07647
(Address of principal executive offices)
(Company’s telephone number, including area code)
| |
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On March 4, 2011, the Company issued a press release informing investors that the US Food and Drug Administration (FDA) announced that it intends to remove certain unapproved cough/cold and allergy related products from the U.S. market. The FDA action impacts approximately 500 products, two of which currently are manufactured by Elite Pharmaceuticals and are marketed by ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal, Co., Inc.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
a) Not applicable.
b) Not applicable.
c) Not applicable.
d) Exhibits
|
Exhibit No.
|
|
Exhibit
|
| |
|
|
|
99.1
|
|
Press Release dated March 4, 2011
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ELITE PHARMACEUTICALS, INC. |
|
| |
|
|
|
|
Dated: March 4, 2011
|
By:
|
/s/ Chris Dick |
|
| |
|
Name: Chris Dick |
|
| |
|
Title: President & Chief Operating Officer |
|
| |
|
|
|